CRGX Stock Overview
A clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
CARGO Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$15.36 |
52 Week High | US$33.92 |
52 Week Low | US$13.14 |
Beta | 0 |
11 Month Change | -19.07% |
3 Month Change | -27.79% |
1 Year Change | n/a |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | 5.71% |
Recent News & Updates
Shareholder Returns
CRGX | US Biotechs | US Market | |
---|---|---|---|
7D | 5.2% | -2.7% | 1.1% |
1Y | n/a | 6.9% | 22.5% |
Return vs Industry: Insufficient data to determine how CRGX performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how CRGX performed against the US Market.
Price Volatility
CRGX volatility | |
---|---|
CRGX Average Weekly Movement | 7.7% |
Biotechs Industry Average Movement | 10.2% |
Market Average Movement | 5.7% |
10% most volatile stocks in US Market | 14.9% |
10% least volatile stocks in US Market | 2.8% |
Stable Share Price: CRGX's share price has been volatile over the past 3 months.
Volatility Over Time: CRGX's weekly volatility (8%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2019 | 123 | Gina Chapman | cargo-tx.com |
CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company’s lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets.
CARGO Therapeutics, Inc. Fundamentals Summary
CRGX fundamental statistics | |
---|---|
Market cap | US$704.44m |
Earnings (TTM) | -US$121.21m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-5.8x
P/E RatioIs CRGX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CRGX income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$121.21m |
Earnings | -US$121.21m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -2.64 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did CRGX perform over the long term?
See historical performance and comparison